Revel has tapped the Agilent Instrument Subscriptions Program to gain access to a mass spectrometer, critical in the startup’s work to combat the damages of aging.

Soteria, a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, announces $42 Million Series A Financing.

Alessa Therapeutics announces the enrollment of the first patient in their clinical study in Australia. The Biolen-PC study will treat up to 20 patients in Australia and New Zealand.